The pharmacological treatment and management of hyperhidrosis

Campanati, Anna; Gregoriou, Stamatis; Milia-Argyti, Adamantia; Kontochristopoulos, George; Radi, Giulia; Diotallevi, Federico; Martina, Emanuela; Offidani, Annamaria

doi:10.1080/14656566.2022.2083499

Cited by 8 publications

(5 citation statements)

References 107 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The reason for this was determined to be due to the extensive formation of collagen fibers following a subcutaneous local injection of sclerosing agents in the axilla 30 years prior to this study, which prevented the sweat gland tissue from entering the microwave negative pressure heating area. 17 At present, the main adverse effects observed in the 20 patients during the follow-up period were related to tissue damage caused by the thermal effects of microwave treatment, which were mild. One patient developed axillary nodules (90 days), and the remaining adverse effects resolved within 5 weeks.…”

Section: Discussionmentioning

confidence: 83%

“…In this study, one patient with axillary hyperhidrosis combined with axillary odor had no significant improvement in either hyperhidrosis or axillary odor symptoms. The reason for this was determined to be due to the extensive formation of collagen fibers following a subcutaneous local injection of sclerosing agents in the axilla 30 years prior to this study, which prevented the sweat gland tissue from entering the microwave negative pressure heating area 17 …”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

The application of microwaves in axillary hyperhidrosis: Curative effect observation of a pathological examination over 1 year

Tan,

Huang,

Liu

et al. 2023

J of Cosmetic Dermatology

View full text Add to dashboard Cite

BackgroundIn Asia, axillary hyperhidrosis is a frequent problem for many people, and the consequent excessive sweating can seriously affect many aspects of daily life and even lead to mental disorders. Microwave therapy is a new, non‐invasive treatment method for axillary hyperhidrosis, whose energy and long‐term effectiveness still needs to be clinically validated.ObjectiveThe aim of this study was to evaluate the clinical efficacy, safety, histological changes, and psychological status of microwave devices in the treatment of axillary hyperhidrosis and osmidrosis.MethodWe conducted a prospective self‐controlled study in a top‐tier Chinese hospital. After a 5/5 energy treatment session, a skin biopsy was taken to observe histological changes both before and after treatment. An iodine starch test was used to determine the sweating range. We evaluated symptoms of improved efficacy using the Hyperhidrosis Disease Severity Scale (HDSS) and assessed changes in life status with the DLQI. In the case of concurrent underarm odor, odor‐5, VAS, and Young‐Jin Park grading were used to assess odor relief. The effect of odor on psychology was assessed by using a psychological status symptom checklist (scl‐90). The study period was 1 year.ResultsWe observed 20 patients in this study. Of those, 90% met the primary treatment endpoint of a decrease in axillary hyperhidrosis symptomatology to below grade 2 on the HDSS score (p < 0.001). Furthermore, 75% of patients achieved a treatment endpoint of at least 50% reduction in VAS (p < 0.001). 70% of patients achieved a treatment endpoint of at least 50% reduction in odor‐5 (p < 0.001). The iodine starch test showed that the region decreased 99% from the baseline to 12 months after follow‐up had ended (p < 0.001). Eight patients volunteered to undergo histological examination; their average light density of immunohistochemistry decreased from 1.04 (0.4–2.11) to 0.07 (0.04–0.46; p < 0.05). The immunohistochemical positive number for sweat glands was initially 104 (59.75–132.5) but was 41.5 (29.75–62) after the procedure. None of the patients experienced any serious adverse reactions.ConclusionThe treatment demonstrated high effectiveness, safety, and short‐lived adverse reactions.

show abstract

Section: Discussionmentioning

confidence: 83%

Section: Discussionmentioning

confidence: 99%

The application of microwaves in axillary hyperhidrosis: Curative effect observation of a pathological examination over 1 year

Tan,

Huang,

Liu

et al. 2023

J of Cosmetic Dermatology

View full text Add to dashboard Cite

show abstract

“…Although treatment may be individualized, most authors and expert panels suggest a step-by-step approach beginning with topical antiperspirants, topical anticholinergics, followed by iontophoresis or BoNT-A injections. [9][10][11][12][13][14][15][16] A recent randomized placebo-controlled trial evaluating the efficacy of oxybutynin 10% gel in patients with focal hyperhidrosis reported a significant reduction of sweating rates, HDSS and DLQI in 12 of 16 patients with PPH who completed the 4 weeks of treatment. 17 In severe cases, systemic anticholinergic agents may be employed, while endoscopic lumbar sympathectomy remains usually the option of last resort.…”

Section: Discussionmentioning

confidence: 99%

“…There are several therapeutic modalities currently available for the treatment of PPH. Although treatment may be individualized, most authors and expert panels suggest a step‐by‐step approach beginning with topical antiperspirants, topical anticholinergics, followed by iontophoresis or BoNT‐A injections 9–16 . A recent randomized placebo‐controlled trial evaluating the efficacy of oxybutynin 10% gel in patients with focal hyperhidrosis reported a significant reduction of sweating rates, HDSS and DLQI in 12 of 16 patients with PPH who completed the 4 weeks of treatment 17 .…”

Section: Discussionmentioning

confidence: 99%

Management of primary plantar hyperhidrosis with botulinum toxin type A: A retrospective case series of 129 patients

Tsiogka,

Agiasofitou,

Tsimpidakis

et al. 2023

Aust J Dermatology

Self Cite

View full text Add to dashboard Cite

Background/ObjectivesTo date, scientific data on the efficacy of botulinum toxin type A (BoNT‐A) for primary plantar hyperhidrosis (PPH) are mainly derived from case reports and small case series. Herein, we sought to assess the efficacy and safety of BoNT‐A for PPH on a large series of patients.MethodsMedical records of patients who were referred to the outpatient department for hyperhidrosis of a tertiary care hospital and received BoNT‐A for PPH from March 2003 until December 2022 were reviewed.ResultsA total of 129 patients [12 males, 117 females; median age 32 years (range, 16–72)] were included in the study, after excluding 24 patients with insufficient documented follow‐up data. Most patients [115 (89.1%)] received onabotulinumtoxin‐A, nine (7.0%) abobotulinumtoxin‐A and five (3.9%) both in subsequent sessions. The mean number of sessions was 2.02 [standard deviation (SD), 2.29] and the mean duration of response 6.16 months (SD, 4.01). The percentage of response, as evaluated by Minor's test, was 71.67%, 63.44%, 47.78% and 34.13% after 1, 3, 6 and 9 months, respectively. Most patients were satisfied (21.7%) or very satisfied (58.9%) with the treatment. No serious side effects were reported.ConclusionsThe results of this retrospective study suggest that BoNT‐A is an effective and safe treatment option for PPH.

show abstract

“…1 Oral anticholinergics are usually recommended for PFH patients with HDSS score of 3 or 4, who have inadequate response to topical aluminium chloride, botulinum toxin type A (BTX-A) or iontophoresis. 1,[6][7][8] In our opinion, systemic treatment should be more thoroughly considered as first-line treatment in MFH, given the significant impact of the disease on daily activities. 8 In our population, the most commonly employed treatment, was oral oxybutynin followed by combination therapy with topical preparations and BTX-A.…”

Section: Characteristic Number Of Patients (%)mentioning

confidence: 99%

Clinical characteristics and treatment options for multifocal hyperhidrosis in a single‐centre real‐world population

Markantoni

Tsiogka

Agiasofitou

et al. 2023

Acad Dermatol Venereol

Self Cite

View full text Add to dashboard Cite

Dear Editor, Primary multifocal hyperhidrosis (MFH) constitutes a phenotype of primary focal hyperhidrosis (PFH) affecting two or more body sites. 1 We sought to describe the demographic, clinical characteristics and management of MFH in a realworld setting.All patients with MFH presenting between December 2016 and December 2020 were included in the study. Diagnostic criteria for PFH were used for inclusion: excessive sweating of at least 6 months, with four or more of the following: involvement of axillae, palms, soles, craniofacial or groin area, bilateral and symmetric, absent during sleep,

show abstract

The pharmacological treatment and management of hyperhidrosis

Cited by 8 publications

References 107 publications

The application of microwaves in axillary hyperhidrosis: Curative effect observation of a pathological examination over 1 year

The application of microwaves in axillary hyperhidrosis: Curative effect observation of a pathological examination over 1 year

Management of primary plantar hyperhidrosis with botulinum toxin type A: A retrospective case series of 129 patients

Clinical characteristics and treatment options for multifocal hyperhidrosis in a single‐centre real‐world population

Contact Info

Product

Resources

About